Literature DB >> 32097509

Distant metastasis of salivary gland cancer: Incidence, management, and outcomes.

Ximena Mimica1, Marlena McGill1, Ashley Hay1, Daniella Karassawa Zanoni1, Jatin P Shah1, Richard J Wong1, Alan Ho2, Marc A Cohen1, Snehal G Patel1, Ian Ganly1.   

Abstract

BACKGROUND: Distant metastases (DMs) are the primary cause of treatment failure in patients with salivary gland carcinoma. There is no consensus on the standard treatment.
METHODS: Patients with DMs were identified from an institutional database of 884 patients with salivary gland cancer who underwent resection of the primary tumor between 1985 and 2015. Survival outcomes for patients with DMs were determined with the Kaplan-Meier method. Univariate and multivariate analyses were performed to identify factors associated with DM.
RESULTS: Of the 884 patients identified, 137 (15%) developed DMs during follow-up. Most of the primary tumors (n = 77 [56%]) were located in a major salivary gland. At clinical presentation, 53% of the tumors were classified as T3 or T4, and 32% had clinical node metastases. The median time to DM was 20.3 months. The factors associated with shorter distant recurrence-free survival were male sex, high-risk tumor histology, and advanced pathological T and N classifications. Patients with bone metastases had a lower survival rate than patients with lung metastases. The total number of DMs in a patient was inversely associated with survival. Patients who underwent surgical resection of DMs had a significantly higher 5-year rate of metastatic disease-specific survival than patients who underwent observation or nonsurgical treatment (44%, 29%, and 19%, respectively; P = .003).
CONCLUSIONS: In patients with DMs of salivary gland carcinoma, survival is negatively associated with high-grade histology, bone DMs, and the total number of DMs. Metastasectomy can help to lengthen disease-free survival.
© 2020 American Cancer Society.

Entities:  

Keywords:  metastasis; salivary gland cancer; surgery; survival

Mesh:

Year:  2020        PMID: 32097509      PMCID: PMC8224983          DOI: 10.1002/cncr.32792

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  25 in total

1.  Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: Incidence and outcomes by site and histological type.

Authors:  Ashley J Hay; Jocelyn Migliacci; Daniella Karassawa Zanoni; Marlena McGill; Snehal Patel; Ian Ganly
Journal:  Cancer       Date:  2019-06-07       Impact factor: 6.860

2.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases.

Authors:  U Pastorino; M Buyse; G Friedel; R J Ginsberg; P Girard; P Goldstraw; M Johnston; P McCormack; H Pass; J B Putnam
Journal:  J Thorac Cardiovasc Surg       Date:  1997-01       Impact factor: 5.209

3.  Lung metastasectomy in adenoid cystic cancer: Is it worth it?

Authors:  Lara Girelli; Laura Locati; Carlotta Galeone; Paolo Scanagatta; Leonardo Duranti; Lisa Licitra; Ugo Pastorino
Journal:  Oral Oncol       Date:  2016-10-26       Impact factor: 5.337

Review 4.  Distant metastases from salivary glands cancer.

Authors:  P J Bradley
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2001 Jul-Aug       Impact factor: 1.538

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Authors:  Allen S Ho; Angelica Ochoa; Gowtham Jayakumaran; Ahmet Zehir; Cristina Valero Mayor; Justin Tepe; Vladimir Makarov; Martin G Dalin; Jie He; Mark Bailey; Meagan Montesion; Jeffrey S Ross; Vincent A Miller; Lindsay Chan; Ian Ganly; Snjezana Dogan; Nora Katabi; Petros Tsipouras; Patrick Ha; Nishant Agrawal; David B Solit; P Andrew Futreal; Adel K El Naggar; Jorge S Reis-Filho; Britta Weigelt; Alan L Ho; Nikolaus Schultz; Timothy A Chan; Luc Gt Morris
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

7.  Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients: A Population-Based, Propensity Score-Adjusted Trend Analysis.

Authors:  Ignazio Tarantino; Rene Warschkow; Mathias Worni; Thomas Cerny; Alexis Ulrich; Bruno M Schmied; Ulrich Güller
Journal:  Ann Surg       Date:  2015-07       Impact factor: 12.969

Review 8.  Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

Authors:  Scott A Laurie; Alan L Ho; Matthew G Fury; Eric Sherman; David G Pfister
Journal:  Lancet Oncol       Date:  2010-12-10       Impact factor: 41.316

9.  Incidence and risk factors of late recurrence in patients with salivary gland cancer.

Authors:  G C Park; J-L Roh; K-J Cho; M H Jin; S-H Choi; S Y Nam; S Y Kim
Journal:  Clin Otolaryngol       Date:  2017-01-08       Impact factor: 2.597

10.  Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma.

Authors:  Hideaki Takahashi; Yuichiro Tada; Takashi Saotome; Kohei Akazawa; Hiroya Ojiri; Chihiro Fushimi; Tatsuo Masubuchi; Takashi Matsuki; Kaori Tani; Robert Y Osamura; Hideaki Hirai; Shuhei Yamada; Daisuke Kawakita; Kouki Miura; Shin-Etsu Kamata; Toshitaka Nagao
Journal:  J Clin Oncol       Date:  2018-11-19       Impact factor: 44.544

View more
  4 in total

1.  Clinical Characteristics and Prognosis of Patients With Pulmonary Mucoepidermoid Carcinoma: A SEER-Based Analysis.

Authors:  Lingxiao Qiu; Pan Song; Pingmei Chen; Huaqi Wang; Fangfang Li; Mengxuan Shu; Gen-Cheng Gong; Xiangjin Song; Chun Huang; Hongxia Jia; Nana Li; Guojun Zhang
Journal:  Front Oncol       Date:  2021-03-05       Impact factor: 6.244

2.  Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.

Authors:  Daisuke Kawakita; Toshitaka Nagao; Hideaki Takahashi; Satoshi Kano; Yoshitaka Honma; Hideaki Hirai; Natsuki Saigusa; Kohei Akazawa; Kaori Tani; Hiroya Ojiri; Kiyoaki Tsukahara; Hiroyuki Ozawa; Kenji Okami; Takahito Kondo; Takafumi Togashi; Chihiro Fushimi; Tomotaka Shimura; Akira Shimizu; Isaku Okamoto; Takuro Okada; Yorihisa Imanishi; Yoshihiro Watanabe; Kuninori Otsuka; Akihiro Sakai; Koji Ebisumoto; Yuichiro Sato; Keisuke Yamazaki; Yushi Ueki; Toyoyuki Hanazawa; Yuki Saito; Mizuo Ando; Takashi Matsuki; Masato Nakaguro; Yukiko Sato; Makoto Urano; Yoshitaka Utsumi; Shinji Kohsaka; Takashi Saotome; Yuichiro Tada
Journal:  Ther Adv Med Oncol       Date:  2022-09-06       Impact factor: 5.485

Review 3.  Estimating survival after salvage surgery for recurrent salivary gland cancers: Systematic review.

Authors:  Giuditta Mannelli; Lara V Comini; Andrea Sacchetto; Roberto Santoro; Giuseppe Spinelli; Pierluigi Bonomo; Isacco Desideri; Paolo Bossi; Ester Orlandi; Giammarco Alderotti; Alessandro Franchi; Annarita Palomba; Albino Eccher; Daniele Marchioni; Riccardo Nocini; Cesare Piazza; Gabriele Molteni
Journal:  Head Neck       Date:  2022-04-20       Impact factor: 3.821

4.  Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma.

Authors:  Kazutomo Niwa; Daisuke Kawakita; Toshitaka Nagao; Hideaki Takahashi; Takashi Saotome; Masashi Okazaki; Keisuke Yamazaki; Isaku Okamoto; Hideaki Hirai; Natsuki Saigusa; Chihiro Fushimi; Tatsuo Masubuchi; Kouki Miura; Shin-Ichi Okazaki; Hirooki Matsui; Takuro Okada; Sho Iwaki; Takashi Matsuki; Kenji Hanyu; Kiyoaki Tsukahara; Nobuhiko Oridate; Yuichiro Tada
Journal:  Sci Rep       Date:  2020-10-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.